Author:
Zhu Zhen-Ning,Feng Qiu-Xia,Li Qiong,Xu Wei-Yue,Liu Xi-Sheng
Abstract
Objective
The purpose of this study is to identify the presence of occult peritoneal metastasis (OPM) in patients with advanced gastric cancer (AGC) by using clinical characteristics and abdominopelvic computed tomography (CT) features.
Methods
This retrospective study included 66 patients with OPM and 111 patients without peritoneal metastasis (non-PM [NPM]) who underwent preoperative contrast-enhanced CT between January 2020 and December 2021. Occult PMs means PMs that are missed by CT but later diagnosed by laparoscopy or laparotomy. Patients with NPM means patients have neither PM nor other distant metastases, indicating there is no evidence of distant metastases in patients with AGC. Patients' clinical characteristics and CT features such as tumor marker, Borrmann IV, enhancement patterns, and pelvic ascites were observed by 2 experienced radiologists. Computed tomography features and clinical characteristics were combined to construct an indicator for identifying the presence of OPM in patients with AGC based on a logistic regression model. Receiver operating characteristic curves and the area under the receiver operating characteristic curve (AUC) were generated to assess the diagnostic performance of the combined indicator.
Results
Four independent predictors (Borrmann IV, pelvic ascites, carbohydrate antigen 125, and normalized arterial CT value) differed significantly between OPM and NPM and performed outstandingly in distinguishing patients with OPM from those without PM (AUC = 0.643–0.696). The combined indicator showed a higher AUC value than the independent risk factors (0.820 vs 0.643–0.696).
Conclusions
The combined indicator based on abdominopelvic CT features and carbohydrate antigen 125 may assist clinicians in identifying the presence of CT OPMs in patients with AGC.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference39 articles.
1. Revisiting the 8th AJCC system for gastric cancer: a review on validations, nomograms, lymph nodes impact, and proposed modifications;Ann Med Surg (Lond),2022
2. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;CA Cancer J Clin,2021
3. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021;Cancer Commun (Lond),2021
4. A bounding box-based Radiomics model for detecting occult peritoneal metastasis in advanced gastric cancer: a multicenter study;Front Oncol,2021
5. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors;Int J Cancer,2014